Belluscura (LSE:BELL) FCF Margin %: -531.85% (As of Jun. 2024)


What is Belluscura FCF Margin %?

Belluscura LSE:BELL FCF Margin % is -531.85% as of Jun. 2024.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Belluscura's Free Cash Flow for the six months ended in Jun. 2024 was £-5.63 Mil. Belluscura's Revenue for the six months ended in Jun. 2024 was £1.06 Mil. Therefore, Belluscura's FCF Margin % for the quarter that ended in Jun. 2024 was -531.85%.

As of today, Belluscura's current FCF Yield % is 0.00%.

The historical rank and industry rank for Belluscura's FCF Margin % or its related term are showing as below:

LSE:BELL' s FCF Margin % Range Over the Past 10 Years
Min: -762.49   Med: 0   Max: 0
Current: -762.49

LSE:BELL's FCF Margin % is not ranked
in the Medical Devices & Instruments industry.
Industry Median: -0.1 vs LSE:BELL: -762.49

Belluscura FCF Margin % Related Terms

Belluscura FCF Margin % Historical Data

* Premium members only.

The historical data trend for Belluscura's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Belluscura FCF Margin % Chart

Belluscura Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
FCF Margin %
Get a 7-Day Free Trial -1,655.10 0.00 -2,328.16 -1,429.09 -1,655.67

Belluscura Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -1,822.59 -1,166.76 -1,931.03 -1,434.71 -531.85

LSE:BELL vs ABT, BSX, SYK: FCF Margin % Comparison

For the Medical Devices subindustry, Belluscura's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Belluscura FCF Margin % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Belluscura's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Belluscura's FCF Margin % falls into.


Belluscura FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Belluscura's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-10.795/0.652
=-1,655.67 %

Belluscura's FCF Margin for the quarter that ended in Jun. 2024 is calculated as

FCF Margin=Free Cash Flow (Q: Jun. 2024 )/Revenue (Q: Jun. 2024 )
=-5.627/1.058
=-531.85 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of -531.85% mean?
Belluscura (LSE:BELL) has a FCF Margin % of -531.85% as of Jun. 2024. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Belluscura and its competitors.
Is Belluscura's FCF Margin % too high?
Belluscura's current FCF Margin % is -531.85%.
How does Belluscura's FCF Margin % compare to ABT and BSX?
Belluscura's FCF Margin % of -531.85% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Belluscura and its competitors. Belluscura's current FCF Margin % is -531.85%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Belluscura stock overvalued right now?
Belluscura (LSE:BELL) has a current FCF Margin % of -531.85%. The current FCF Margin % is -531.85%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Belluscura (LSE:BELL), the current FCF Margin % is -531.85% as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Belluscura Business Description

Address 15 Fetter Lane, Holborn, London, GBR, EC4A 1BW
Belluscura PLC is a medical device company. Its first product, the X-PLOR, is a lightweight FDA-cleared portable oxygen concentrator designed to replace larger, metal oxygen tanks and heavier portable oxygen concentrator devices. The company has only one operating segment being the sale of oxygen concentrators in the United States. The X-PLO2R weighs less than 1.5kg (3.25 lbs) and it is the first modular portable oxygen concentrator it will generate more oxygen by weight than any other FDA-cleared POC in its class. It either owns or exclusively licenses a total of 26 patents and applications relating to oxygen enrichment devices and treatments.